Dimerix draws down $17M funding facility

Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility

Dimerix has drawn down $17 million under its non-dilutive debt facility.
The funding extends the company's financial runway without diluting existing shareholder equity.
Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial.

Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline.

The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders.

"The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and the advancement of DMX-652," said Dimerix CEO and Managing Director Dr Nina Webster.

The facility incurs an interest rate of 10% per annum compounding annually, with full repayment due by Jan. 17, 2028.

Dimerix stated that drawing only half of the facility minimises financing costs while maintaining the flexibility to access the remaining balance before 31 March 2027.

Following the announcement, the Dimerix share price was up at $0.24.

The biopharmaceutical business remains focused on developing new therapies for inflammatory and kidney diseases with unmet medical needs.

Its lead candidate DMX-200 is currently being evaluated in late-stage clinical trials for focal segmental glomerulosclerosis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":610863435055920,"tweetId":"610863435055920","gmtCreate":1790156012304,"gmtModify":1790156021492,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":255,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/2a3796401ea4c41a97d5e484d11bf95c","width":"1456","height":"816"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/2a3796401ea4c41a97d5e484d11bf95c","width":"1456","height":"816"}],"title":"Dimerix draws down $17M funding facility","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a3796401ea4c41a97d5e484d11bf95c\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility</p>\n<ul>\n <li>\n  <p>Dimerix has drawn down $17 million under its non-dilutive debt facility.</p></li>\n <li>\n  <p>The funding extends the company's financial runway without diluting existing shareholder equity.</p></li>\n <li>\n  <p>Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial.</p></li>\n</ul>\n<p style=\"text-align: start;\">Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline.</p>\n<p style=\"text-align: start;\">The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders.</p>\n<p style=\"text-align: start;\">\"The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and the advancement of DMX-652,\" said Dimerix CEO and Managing Director Dr Nina Webster.</p>\n<p style=\"text-align: start;\">The facility incurs an interest rate of 10% per annum compounding annually, with full repayment due by Jan. 17, 2028.</p>\n<p style=\"text-align: start;\">Dimerix stated that drawing only half of the facility minimises financing costs while maintaining the flexibility to access the remaining balance before 31 March 2027.</p>\n<p style=\"text-align: start;\">Following the announcement, the Dimerix share price was up at $0.24.</p>\n<p style=\"text-align: start;\">The biopharmaceutical business remains focused on developing new therapies for inflammatory and kidney diseases with unmet medical needs.</p>\n<p style=\"text-align: start;\">Its lead candidate DMX-200 is currently being evaluated in late-stage clinical trials for focal segmental glomerulosclerosis.</p>\n<p></p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2a3796401ea4c41a97d5e484d11bf95c\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility</p>\n<ul>\n <li>\n  <p>Dimerix has drawn down $17 million under its non-dilutive debt facility.</p></li>\n <li>\n  <p>The funding extends the company's financial runway without diluting existing shareholder equity.</p></li>\n <li>\n  <p>Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial.</p></li>\n</ul>\n<p style=\"text-align: start;\">Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline.</p>\n<p style=\"text-align: start;\">The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders.</p>\n<p style=\"text-align: start;\">\"The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and the advancement of DMX-652,\" said Dimerix CEO and Managing Director Dr Nina Webster.</p>\n<p style=\"text-align: start;\">The facility incurs an interest rate of 10% per annum compounding annually, with full repayment due by Jan. 17, 2028.</p>\n<p style=\"text-align: start;\">Dimerix stated that drawing only half of the facility minimises financing costs while maintaining the flexibility to access the remaining balance before 31 March 2027.</p>\n<p style=\"text-align: start;\">Following the announcement, the Dimerix share price was up at $0.24.</p>\n<p style=\"text-align: start;\">The biopharmaceutical business remains focused on developing new therapies for inflammatory and kidney diseases with unmet medical needs.</p>\n<p style=\"text-align: start;\">Its lead candidate DMX-200 is currently being evaluated in late-stage clinical trials for focal segmental glomerulosclerosis.</p>\n<p></p></body></html>","text":"Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility Dimerix has drawn down $17 million under its non-dilutive debt facility. The funding extends the company's financial runway without diluting existing shareholder equity. Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial. Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline. The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders. \"The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and the advancement of DMX-652,\" said Dimerix CEO and Managing Director Dr Nina Webster. The facility incurs an interest rate of 10% per annum compounding annually, with full repayment due by Jan. 17, 2028. Dimerix stated that drawing only half of the facility minimises financing costs while maintaining the flexibility to access the remaining balance before 31 March 2027. Following the announcement, the Dimerix share price was up at $0.24. The biopharmaceutical business remains focused on developing new therapies for inflammatory and kidney diseases with unmet medical needs. Its lead candidate DMX-200 is currently being evaluated in late-stage clinical trials for focal segmental glomerulosclerosis.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/610863435055920","repostId":0,"isVote":1,"tweetType":1,"viewCount":0,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1295,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/610863435055920"}